Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

1.2K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
Rh Blood Group01:19

Rh Blood Group

4.3K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
4.3K
Transcytosis of IgG01:15

Transcytosis of IgG

3.4K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
3.4K
Teratogenicity01:07

Teratogenicity

4.2K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

168
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
168

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to the Letter to the Editor Entitled "Integrating Tissue Proteomics and Urinary Analysis to Capture Dynamic Podocyte Injury".

Kidney international reports·2026
Same author

Autoantibodies reactive with glomerular endothelial cells and podocytes in patients with membranous nephropathy.

Journal of translational autoimmunity·2026
Same author

Mass Spectrometry of Minimal Change Disease and Focal Segmental Glomerulosclerosis.

Kidney international reports·2025
Same author

Identification of early predictors of clinical remission in primary membranous nephropathy: a <i>post hoc</i> analysis of the STARMEN trial.

Clinical kidney journal·2025
Same author

Microphysiological Glomerular Filtration Barriers: Current Insights, Innovations, and Future Applications.

Advanced biology·2025
Same author

Anti-nephrin antibodies guide living donor kidney transplantation in a pediatric patient with primary focal segmental glomerular sclerosis.

Kidney international·2025

Related Experiment Video

Updated: May 5, 2026

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface
07:51

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface

Published on: May 21, 2015

17.0K

[Anti-CD 10 maternal-fetal allo-immunisation].

Pierre Ronco1, Hanna Debiec

  • 1Unité INSERM UMR S 702, UPMC Université Paris 6, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Paris. pierreronco@yahoo.fr

Bulletin De L'Academie Nationale De Medecine
|December 10, 2013
PubMed
Summary

Maternal-fetal alloimmunisation causes antenatal glomerulopathies (FMAIG) when maternal antibodies target fetal kidney cells. This novel disorder necessitates antigen-driven therapies to protect future pregnancies.

More Related Videos

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C
07:13

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C

Published on: March 25, 2016

18.7K
Isolation of Leukocytes from the Human Maternal-fetal Interface
08:19

Isolation of Leukocytes from the Human Maternal-fetal Interface

Published on: May 21, 2015

15.7K

Related Experiment Videos

Last Updated: May 5, 2026

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface
07:51

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface

Published on: May 21, 2015

17.0K
Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C
07:13

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C

Published on: March 25, 2016

18.7K
Isolation of Leukocytes from the Human Maternal-fetal Interface
08:19

Isolation of Leukocytes from the Human Maternal-fetal Interface

Published on: May 21, 2015

15.7K

Area of Science:

  • Immunology
  • Nephrology
  • Maternal-Fetal Medicine

Background:

  • Maternal-fetal alloimmunisation with antenatal glomerulopathies (FMAIG) is a newly identified allo-immune condition.
  • It arises from maternal antibodies targeting fetal glomerular podocytes, leading to renal dysfunction.
  • Pathogenic antibodies are directed against CD10/neutral endopeptidase (NEP).

Discussion:

  • The condition occurs when a genetically NEP-deficient mother produces antibodies against fetal CD10/NEP.
  • This is the first described organ-specific disorder resulting from maternal-fetal alloimmunisation.
  • Diagnosed in five families, highlighting its clinical significance.

Key Insights:

  • Maternal antibodies cross the placenta and bind to fetal glomerular podocytes.
  • Fetal kidney dysfunction is caused by these alloantibodies.
  • The mother's NEP deficiency is the underlying cause of her immunization.

Outlook:

  • Future pregnancies in affected mothers face high fetal risk.
  • Urgent need for antigen-driven therapies to eliminate pathogenic antibodies.
  • Identification of pathogenic epitopes is crucial for developing targeted treatments.